Additional doses of SARS-CoV-2 vaccine heighten antibody response in patients with IBD
SAN DIEGO — Seroconversion rates and antibody response significantly increased after a third dose of SARS-CoV-2 vaccine in patients with inflammatory bowel disease, according to a presenter at Digestive Disease Week 2022.“Third- and fourth-dose responses were significantly stronger than a two-dose regimen,” Joshua Quan, MSc, a master’s student at the University of Calgary Cumming School of Medicine, told attendees. “Also, the antibody responses decayed over time from second- to third-dose vaccination, which really highlights the need for third-dose vaccination.”Read More
